公开(公告)号：US09856253B2

公开(公告)日：2018-01-02

申请号：US15130362

申请日：2016-04-15

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton Longenecker ,  Augustine Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel Wilson

IPC: C07D227/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00 ,  C07D471/18 ,  C07D491/147 ,  C07D491/22

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20170349589A9

公开(公告)日：2017-12-07

申请号：US14972482

申请日：2015-12-17

Applicant: AbbVie Inc.

Inventor： Yujia Dai ,  William McClellan ,  Mike Michaelides ,  Ramzi Sweis ,  Noel Wilson ,  Justin Dietrich

IPC: C07D473/34 ,  C07D519/00 ,  C12Q1/48

CPC classification number: C07D473/34 ,  C07D519/00 ,  C12Q1/48 ,  G01N2333/91017 ,  G01N2500/04

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).